ReviewStem cells and cloning : advances and applications2018
A review on stem cell therapy for multiple sclerosis: special focus on human embryonic stem cells.
Review in Stem cells and cloning : advances and applications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 51 citations in OpenAlex.
- Investigating theResearch in pharmaceutical sciences · 2026Article
- Progressive multiple sclerosis: Evaluating current therapies and exploring future treatment strategies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Comprehending Alzheimer's Disease: Molecular Mechanisms and Treatment Strategies.Current Alzheimer research · 2025Review
- CD34 Protein: Its expression and function in inflammation.Cell and tissue research · 2023Review
- Stem Cells and Natural Agents in the Management of Neurodegenerative Diseases: A New Approach.Neurochemical research · 2023Review
- Mesenchymal stem cell therapy: A review of clinical trials for multiple sclerosis.Regenerative therapy · 2022Review
- Forthcoming complications in recovered COVID-19 patients with COPD and asthma; possible therapeutic opportunities.Cell communication and signaling : CCS · 2022Review
- Regenerative Neurology and Regenerative Cardiology: Shared Hurdles and Achievements.International journal of molecular sciences · 2022Review
- Review
- Standard Operating Procedure for the Good Manufacturing Practice-Compliant Production of Human Endometrial Stem Cells for Multiple Sclerosis.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Innovation in unruptured intracranial aneurysm coiling: At which price or efficacy are new technologies cost-effective?PloS one · 2021Article
- Article
- Comparison of The Expression of miR-326 between Interferon beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis.Cell journal · 2020Article
- Informatics Approaches for Harmonized Intelligent Integration of Stem Cell Research.Stem cells and cloning : advances and applications · 2020Review
- Safety and efficacy of stem cell therapy for treatment of neural damage in patients with multiple sclerosis.Stem cell investigation · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS), a complex disorder of the central nervous system (CNS), is characterized with axonal loss underlying long-term progressive disability. Currently available therapies for its management are able to slow down the progression but fail to treat it completely. Moreover, these therapies are associated with major CNS and cardiovascular adverse events, and prolonged use of these treatments may cause life-threatening diseases. Recent research has shown that cellular therapies hold a potential for CNS repair and may be able to provide protection from inflammatory damage caused after injury. Human embryonic stem cell (hESC) transplantation is one of the promising cell therapies; hESCs play an important role in remyelination and help in preventing demylenation of the axons. In this study, an overview of the current knowledge about the unique properties of hESC and their comparison with other cell therapies has been presented for the treatment of patients with MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.